Vaccination as immunotherapy for B cell lymphoma

Hematological Oncology

Volumn 15, Issue 3, 1997, Pages 129-139

  Schultze, Joachim L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD40; Idiotype; Lymphoma

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; CANCER CELL; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, EXPERIMENTAL; LYMPHOMA, B-CELL; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, B-CELL; T-LYMPHOCYTE SUBSETS; TRANSFECTION; TUMOR STEM CELLS; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0031409939     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1069(199708)15:3<129::AID-HON607>3.0.CO;2-N     Document Type: Article

References (91)

1. Rohatiner, A., Lister, T. A. Management of follieular lymphoma. Curr. Opin. Oncol. 1994, 6, 473-479.
2. Shepherd, J. D., Phillips, G. L. High-dose therapy for lymphoma. Curr. Opin Oncol. 1993, 5, 797-804.
3. Straneo, M., Gianni, L. New active drugs in the treatment of lymphomas. Curr. Opin. Oncol. 1994, 6, 480-488.
4. von Gunten, C. F., Gordon, L. I. Treatment of advanced, aggressive non-Hodgkin's lymphoma. Curr. Opin. Oncol. 1993, 5, 791-796.
5. Pardoll, D. M. A new look for the 1990s. Nature 1994, 369, 357-358.
6. Pardoll, D. M. Cancer vaccines. Immunol. Today 1993, 14, 310-313.
7. Krolick, K. A., Isakson, P.C., Uhr, J. W., Vitetta, E. S. BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol. Rev. 1979 481, 81-106.
8. Hsu, F. J., Kwak, L., Campbell, M., et al. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann. N. Y. Acad. Sci. 1993, 690, 385-387.
9. Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., Levy, R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992, 327, 1209-1215.
10. Kwak, L. W., Campbell, M., Levy, R. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect. Prevent. 1991, 15, 323-325.
11. Kwak, L. W., Young, H. A., Pennington, R. W., Weeks, S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. U.S.A. 1996, 92, 10972-10977.
12. Tao, M. H., Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993, 362, 755-758.
13. Chen, T. T., Tao, M. H., Levy, R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 1994, 153, 4775-47787.
14. Hawkins, R. E., Winter, G., Hamblin, T. J., Stevenson, F. K., Russell, S. J. A genetic approach to idiotypic vaccination. J. Immunother. 1993, 14, 273-278.
15. Stevenson, F. K., Zhu, D., King, C. A., Ashworth, L. J., Kumar, S., Hawkins, R. E. Idiotype DNA vaccines against B-cell lymphoma. Immunol. Rev. 1995, 145, 211-228.
16. Syrengelas, A. D., Chen, T. T., Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 1996, 2, 1038-1041.
17. Flamand, V., Sornasse, T., Thielemans, K., et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 1994, 24, 605-610.
18. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Leo, O., Urbain, J. M. M. Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to B cell lymphoma. Adv. Exptl. Med. Biol. 1993, 329, 611-616.
19. Flamand, V., Lespagnard, L., Thielemans, K., Leo, O., Urbain, J., Moser, M. Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor. Ann. N. Y. Acad. Sci. 1993, 690, 382-384.
20. Hsu, F. J., Benike, C., Fagnoni, F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996, 2, 52-58.
21. Schultze, J. L., Michalak, S., Seamon, M. J., et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. Nat. Med. 1997.
22. Dranoff, G., Jaffee, E., Lazenby, A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3539-3543.
23. Levitsky, H. I., Montgomery, J., Ahmadzadeh, M., et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 1996, 156, 3858-3865.
24. Schultze, J. L., Cardoso, A. A., Freeman, G. J., et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Nail. Acad. Sci. U.S.A. 1995, 92, 8200-8204.
25. Schultze, J. L., Seamon, M. J., Michalak, S., Gribben, J. G., Nadler, L. M. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997, 89, 3806-3816.
26. Eichmann, K., Emmrich, F., Kaufmann, S. H. Idiotypic vaccinations: consideration towards a practical application. Crit. Rev. Immunol. 1987, 7, 193-227.
27. Bogen, B., Weiss, S. Processing and presentation of idiotypes to MHC-restricted T cells. Internat. Rev. Immunol. 1993, 10, 337-355.
28. Stevenson, F. K., Zhu, D., King, C. A., et al. A genetic approach to idiotypic vaccination for B cell lymphoma. Ann. N. Y. Acad. Sci. 1995, 772, 212-226.
29. Weiss, S., Bogen, B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 282-286.
30. Chakrabarti, D., Ghosh, S. K. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype. Cell. Immunol. 1992, 144, 455-464.
31. Weiss, S., Bogen, B. MHC class II-restricted presentation of intracellular antigen. Cell 1991, 64, 767-776.
32. King, C. A., Wills, M. R., Hamblin, T. J., Stevenson, F. K. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell. Immunol. 1993, 147, 411-424.
33. Bogen, B., Munthe, L., Sollien, A., et al. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur. J. Immunol. 1995, 25, 3079-3086.
34. Wilson, A., George, A. J., King, C. A., Stevenson, F. K. Recognition of a B cell lymphoma by anti-idiotypic T cells. J. Immunol. 1990, 145, 3937-3943.
35. Lauritzsen, G. F., Weiss, S., Dembic, Z., Bogen, B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad Sci. U.S.A. 1994, 91, 5700-5704.
36. Lauritzsen, G. F., Bogen, B. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell. Immunol. 1993, 148, 177-188.
37. Lauritzsen, G. F., Weiss, S., Bogen, B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand. J. Immunol. 1993, 37, 77-85.
38. Lauritzsen, G. F., Bogen, B. Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type. Scand. J. Immunol. 1991, 33, 647-656.
39. Bogen, B., Dembic, Z., Weiss, S. Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J. 1993, 12, 357-363.
40. Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C., Levy, R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 1990, 145, 1029-1036.
41. George, A. J., Tutt, A. L., Stevenson, F. K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 1987, 138, 628-634.
42. Ciavarra, R. P., Viotetta, E. S., Forman, J. Growth inhibition of a B cell leukemia.: evidence implicating an anti-idiotype immune response for protective tumor immunity. J. Immunol. 1986, 137 1371-1375.
43. Levy, R., Dilley, J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc. Natl. Acad Sci. U.S.A. 1978, 75, 2411-2415.
44. Hawkins, R. E., Zhu, D., Ovecka, M., et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 1994, 83, 3279-3288.
45. Nelson, E. L., Li, X., Hsu, F. J., et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell non-Hodgkin's lymphoma. Blood 1996, 88, 580-589.
46. George, A. J., Folkard, S. G., Hamblin, T. J., Stevenson, F. K. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 1988, 141, 2168-2174.
47. Stevenson, F. K. Update on tumor vaccines. Int. J. Clin. Lab. Res. 1992, 22, 84-89.
48. Stevenson, F. K., George, A. J., Glennie, M. J. Anti-idiotypic therapy of leukemias and lymphomas. Chem. Immunol. 1990, 48, 126-166.
49. Kwak, L. W., Taub, D. D., Duffey, P. L., et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345, 1016-1020.
50. Kwak, L. W., Campbell, M. J., Zelenetz, A. D., Levy, R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood 1991, 78, 2768-2772.
51. Kwak, L. W., Campbell, M. J., Zelenetz, A. D., Levy, R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990, 76, 2411-2417.
52. Kwak, L. W., Pennington, R., Longo, D. L. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996, 87, 3053-3060.
53. Dyke, R. J., McBride, H., George, A. J., Hamblin, T. J., Stevenson, F. K. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell. Immunol. 1991, 132, 70-83.
54. Chen, T. T., Levy, R. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J. Immunol. 1995, 154, 3105-3117.
55. Bahler, D. W., Levy, R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 677-6774.
56. Berinstein, N., Campbell, M. J., Lam, K., Carswello, C., Levy, S., Levy, R. Idiotypic variation in a human B lymphoma cell line. J. Immunol. 1990, 144, 752-758.
57. Zelenetz, A. D., Chen, T. T., Levy, R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J. Exptl. Med. 1992, 176, 1137-1148.
58. George, A. J., Foreman, R. C., Stevenson, F. K. Characterisation of a light chain loss variant of the BCL1 lymphoma. Mol. Immunol. 1991, 28, 789-799.
59. Zelenetz, A. D., Campbell, M. J., Bahler, D. W., et al. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann. Oncol. 1991, 2(Suppl. 2), 115-122.
60. George, A. J., Spellerberg, M. B., Stevenson, F. K. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics. J. Immunol. 1988, 140, 1695-1701.
61. Dranoff, G., Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol. 1995, 58, 417-454.
62. Ostrand-Rosenberg, S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 1994, 6, 722-727.
63. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P., Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994, 12, 337-365.
64. Van Pel, A., van der Bruggen, P., Coulie, P., et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 1995, 145, 229-250.
65. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., Nadler, L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994, 84, 3261-3282.
66. Schultze, J. L., Nadler, L. M., Gribben, J. G. B7-mediated costimulation and the immune response. Blood Rev. 1996, 10, 111-127.
67. Sharpe, A. H. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr. Opin. Immunol. 1995, 7, 389-395.
68. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., Glimcher, L. H. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. U.S.A. 1993, 90 5687-5690.
69. Chen, L., Linsley, P. S., Hellstrom, K. E. Costimulation of T cells for tumor immunity. Immunol. Today 1993, 14, 483-486.
70. Harding, F. A., Allison, J. P. CD28-B7 Interactions allow the induction of CDS+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exptl. Med. 1993, 177, 1791-1796.
71. Townsend, S. E., Allison, J. P. Tumor rejection after direct costimulation of CDS+ T cells by B7-transfected melanoma cells. Science 19093, 259, 368-370.
72. Allison, J. P., Hurwitz. A. A., Leach, D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 1995, 7, 682-686.
73. Hellstrom, K. E., Hellstrom, I, Chen, L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 1995, 145, 123-145.
74. Chen, L., McGowan, P., Ashe, S., et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exptl. Med. 1994, 179, 523-532.
75. Huang, A. Y., Bruce, A. T., Paradoll, D. M., Levitsky, H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exptl. Med. 1996, 183, 769-776.
76. Wu, T.-C., Huang, A. Y. C., Jaffee, E. M., Levitsky, H. I., Pardoll, D. M. A reassessment of the role of B7-1 expression in tumor rejection. J. Exptl. Med. 1995, 182, 1415-1421.
77. Huang, A. Y., Bruce, A. T., Pardoll, D. M., Levitsky, H. I. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996, 4, 349-355.
78. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264, 961-965.
79. Baskar, S., Glimcher, L., Nabavi, N., Jones, R. T., Ostrand-Rosenberg, S. Major histocompatibility complex class II+B7-1 tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exptl. Med. 1995, 181, 619-629.
80. Topalian, S. L. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 1994, 6, 741-745.
81. Matulonis, U., Dosiou, C., Freeman, G., et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 1996, 156, 1126-1131.
82. Matulonis, U. A., Dosiou, C., Lamont, C., et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995, 85, 2507-2515.
83. Gajewski, T. F., Fallarino, F., Uyttenhove, C., Boon, T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 1996, 156, 2909-2917.
84. Gajewski, T. F. B7-1 but not B7-2 efficiently costimulated CD8+ T lymphocytes in the P815 tumor system in vitro. J. Immunol. 1996, 156, 465-472.
85. Munro, J. M., Freedman, A. S., Aster, J. C., et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994, 83, 793-798.
86. Schultze, J. L. Unpublished results. 1997.
87. Croft, M., Bradley, L. M., Swain, S. L. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 1994, 152, 2675-2685.
88. Lanzavecchia, A. Identifying strategies for immune intervention. Science 1993, 260, 937-944.
89. Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992, 71 1065-1068.
90. Banchereau, J., Bazan, F., Blanchard, D., et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994, 12, 881-922.
91. Faassen, A. E., Dalke, D. P., Berton, M. T., Warren, W. D., Pierce, S. K. CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur. J. Immunol. 1996, 25, 3249-3255.